Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Johnson & Johnson (

Ambrx Biopharma soars on $2 billion takeover by Johnson & Johnson

Ambrx Biopharma is the latest cancer-drug specialist to be bought by a larger pharma over the past year.

The Street

Will Matthew Perry’s death spell the end of the ketamine wellness industry?

The actor’s autopsy revealed he had died from taking ketamine, currently being touted as a miracle treatment for mental health problems

The Guardian - US

In 2023, opioid settlement funds flowed to states. Here's how it's going

Some $1.5 billion flowed to local government coffers this year, sparking debates about transparency and how to spend the money. Here are 5 takeaways from a year's worth of reporting on the issue.

WEKU

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Solid Pharma Stocks for a Healthy Year-End Portfolio

The pharma industry is transforming due to the rapid adoption of AI and global healthcare spending, fostering innovation and patient care advancements. Therefore, fundamentally sound pharma stocks Eli Lilly (LLY), Wave Life Sciences (WVE) and Johnson & Johnson (JNJ) might be worth adding to boost your portfolio. Continue reading.

StockNews.com

A CEO contender left Johnson & Johnson. Was she penalized for saying she wanted the job?

The exit of a Johnson & Johnson exec raises an age-old question about women's ambition.

Fortune

His dad worked on the factory floor at Johnson & Johnson. Now he’s the CFO

Joe Wolk, with J&J for over 25 years, talks about his path and the company's focus on innovation.

Fortune

Bristol Myers slumps as Bayer trial failure casts doubt on $5 billion drug

German drugmaker Bayer scrapped a late-stage trial of an experimental blood thinner that could have major implications for Bristol Myers.

The Street

Read news from The Economist, FT, and more,
with one subscription

Breakthrough antidepressants with fewer side effects could help millions of Americans. Here's what the future of treatment may look like

As Americans are increasingly reaching for pharmaceutical solutions for depression—about one in eight U.S. adults takes antidepressants—scientists have been innovating novel treatments for it.

Fortune

Should You Invest in Johnson & Johnson (JNJ) Following Q3 Results

Johnson & Johnson’s (JNJ) third-quarter results impressed investors, as its earnings and revenue beat Wall Street estimates. Should investors consider investing in the stock following the solid third-quarter results? Read on to learn my view….

StockNews.com

Massive consumer brand, Johnson & Johnson pursues bankruptcy filing

The company openly talked about a potential Chapter 11 filing during its most recent earnings call.

The Street

Johnson & Johnson Raises Outlook As The Health Care Bellwether Beats Views

Johnson & Johnson beat third-quarter forecasts Tuesday and raised its outlook for the year. JNJ stock skidded lower after the open.

Investors Business Daily

Stocks edge lower, retail sales on deck, Goldman Sachs, United Airlines, Johnson & Johnson earnings - 5 Things To Know

Stocks lower, retail sales, Goldman Sachs, United Airlines, Johnson & Johnson

The Street

Johnson & Johnson earnings top forecasts on new cancer drug boost

Johnson & Johnson's newly-structured business, which no longer includes a consumer healthcare unit, is seeing solid demand for its new cancer-focused treatments Carvykti and Tecvayli.

The Street

3 Dividend Aristocrats to Defend Your Portfolio in Q4

In the midst of economic uncertainty, look to the likes of Procter & Gamble, Coca-Cola, and Johnson & Johnson as steadfast investment options, offering relative stability and reliable income for Q4 2023 and beyond.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

How big companies from EY to Johnson & Johnson are learning to master AI prompts

Embracing AI is the easy part—firms have already moved on to harder parts like making AI actually work for their business.

StockNews.com

Johnson & Johnson (JNJ) vs. Madrigal Pharmaceuticals (MDGL): Which Pharma Stock Is a Worthier October Investment?

With an aging population worldwide, the growing prevalence of chronic diseases, new drug discoveries and rapid digital advancements, the outlook for the pharmaceutical sector remains optimistic. Pharma stocks Johnson & Johnson (JNJ) and Madrigal Pharmaceuticals (MDGL) will likely benefit from the industry’s bright prospects. But which of these stocks is…

Fortune

Generative AI is top of mind for all types of leaders, from Treasury Secretary Janet Yellen to J&J CEO Joaquin Duato

This week’s episode of Fortune‘s Leadership Next podcast features conversations from the Fortune CEO Initiative conference.

Barchart

Three Stocks To Help You Through the Financial Roller Coaster!

The Middle East is back in focus as tensions broke. But, what can investors own to weather the storm?

Get all your
news in one place.

100’s of premium titles.
One news app.

USA Today Sports Media Group

Travis Kelce shakes off Aaron Rodgers dig: ‘I’m fully comfortable with him calling me Mr. Pfizer’

Mr. Pfizer and his mustache are doing just fine.

Sports Illustrated

Chiefs’ Travis Kelce Responds to Aaron Rodgers’s ‘Mr. Pfizer’ Jab

“Who knew I’d get into the vax wars with Aaron Rodgers, man?”

USA Today Sports Media Group

Aaron Rodgers oddly called Travis Kelce ‘Mr. Pfizer’ despite playing for the Johnson & Johnson heir

Aaron Rodgers can be such a dork, man.

Fortune

In rare interview, J&J CEO Joaquin Duato opens up about Baby Powder cancer lawsuits and the future of Kenvue

J&J CEO Joaquin Duato's interview on Baby Powder cancer lawsuits, Kenvue, and the COVID vaccine.

Barchart

Johnson & Johnson Stock Looks Like Good Value Now

Johnson & Johnson stock (JNJ) recently spun off its consumer Kenvue business, which trades separately under the symbol KVUE. However, JNJ stock has dipped and now looks like good value.

Barchart

Protect Your Returns With These 3 Dividend Kings!

Looking for long-term income and stability? Here's 3 dividend kings you won't want to miss!

Barchart

Protect Your Returns With These Three Dividend Kings!

Looking for long-term income and stability? Here's 3 dividend kings you won't want to miss!

1 … 4 5 6 7

People

Dipanjan BanchurSince

722 stories

Pat McAfee

629 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.